Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Charles River Laboratories (CRL)

Charles River Labs extends CEO Foster's contract to 2027; shareholders re-elect seven directors

Neutral Impact 3 of 5 leadership Written later

Charles River Laboratories amended CEO James Foster's employment agreement on May 20, 2025, extending his term by one year to February 12, 2027, with all other terms unchanged. At the same meeting, shareholders re-elected seven directors, approved executive pay on an advisory basis, ratified PricewaterhouseCoopers as auditor, and rejected a PETA-submitted proposal on non-human primates.

Key points

  • Foster employment term extended one year to February 12, 2027; other terms unchanged
  • Seven directors elected to serve until the 2026 Annual Meeting; Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves appointed to the Board
  • Advisory vote on executive compensation: 40,218,870 for and 1,432,240 against
  • PETA proposal on non-human primates not approved: 3,457,547 for and 38,051,509 against

The filing

CompanyCharles River Laboratories (CRL)
Form8-K, current report
Filed with the SECMay 23, 2025, 4:12 PM ET
Accession number0001100682-25-000023

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:11 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 23, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.